by Peter Ciszewski | Jul 10, 2020
Steve Noga, MD, of Takeda Oncology discusses the latest results of the ongoing US MM-6 RW clinical trial, examining the effectiveness and safety of an in-class transition to ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple...
by Peter Ciszewski | Jul 9, 2020
Donald Lo, PhD, Director of the National Center for Advancing Translational Sciences (NCATS), discusses NCATS and its mission as an organization. Dr. Lo notes the primary goal of NCATS is to help organizations navigate what he calls the “Valley of Death”...
by Peter Ciszewski | Jul 8, 2020
Federico Grossi, MD, Chief Medical Officer at Apellis Pharmaceuticals, discusses the results of the PEGASUS study, a phase 3 clinical trial testing pegcetacoplan vs eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare,...
by Peter Ciszewski | Jul 7, 2020
John Leonard, MD of Weill Cornell Medicine discusses follicular lymphoma. Follicular lymphoma is the second most common non-Hodgkin lymphoma accounting for approximately 15% of all lymphomas in North America. Presentation of follicular lymphoma includes...
by Peter Ciszewski | Jul 6, 2020
Susan Samson, MD, PhD of Baylor College of Medicine talks about the recently approved Mycapssa (octreotide) capsules as long-term maintenance therapy for people with acromegaly. Mycapssa is the only oral form of octreotide, a somatostatin analog, approved by...
